This workshop is designed to provide a forum for participants from across the medicinal cannabis industry, and particularly medicinal cannabis companies and research organisations, to discuss approaches to successfully engaging with HREC in the area of clinical trials involving unregistered medicinal cannabis therapeutic goods.
MCIA is supporting this to assist in enabling and encouraging robust clinical research in the sector.
Date: 28 October 2022 Time: 11:00am – 1.00pm (AEST) Virtual: Zoom link will be provided when you register
The workshop will cover:
Sponsor obligations and responsibilities
Botanical drug product and quality control
Dr Melinda Thompson, Head of Regulatory Affairs & Quality Systems Source Certain and Chair of MCIA Research Working Group
Professor Andrew McLachlan, Head of School & Dean of Pharmacy, University of Sydney
ACannabis has established itself as a professional, credible industry event on the Australian medicinal cannabis calendar. Speakers, partners and delegates continue to rate the conference highly for format, content and organisation and we can’t wait to come back face to face in 2023.
Olivia was an inspirational and vocal advocate for medicinal cannabis. She knew the important role medicinal cannabis could play in the journey of a cancer patient and was passionate about increased patient access.
When MCIA launched, she was excited to see the industry come together to discuss these important issues to ensure all patients had access to medicinal cannabis.
Please join MCIA and industry colleagues for a fireside chat and networking function. Daniel Rooney (Insurance broker, Marsh) will be in conversation with Will Clarke (Underwriter, NewLine) to discuss Understanding Clinical Trials and Insurance Requirements. Will and Daniel will discuss the in’s and outs of clinical trials, where claims typically occur and how to make sure you have the right protection in place
Medicinal Cannabis Industry Australia (MCIA) has released a roadmap that outlines opportunities for the sector and strategic levers that need to be addressed to enable the sector to capitalise on these opportunities.
ACannabis is back in 2022. With the theme, ‘Bridging the gap: evidence, confidence, access‘, ACannabis will be held over two jam packed days, Tuesday 15th March to Wednesday 16th March, and is the one location to stay up to date with all facets of the medicinal cannabis industry. Due to the ever changing landscape, ACannabis 2022 will be a virtual conference and exhibition with a wide range of networking opportunities available. It will be immersive, engaging and deliver an:
Please join us for the inaugural MCIA networking event to socialise, celebrate and contribute ideas for developing future networking events! Each occasion will include a speaker and presentation on a topic of interest to the industry.
Developed by MTPConnect in partnership with Deloitte Access Economics, MCIA was pleased to initiate consultation with MTPConnect to develop this evidence based report for the industry and we thank MTPConnect for their support and work in developing this resource.
Medicinal Cannabis Industry Australia (MCIA) is pleased to partner with FreshLeaf for the third year running in the release of FreshLeaf’s latest comprehensive analysis of medicinal cannabis products, pricing and patients.
MCIA is excited to invite you to an exclusive webinar hosted by FreshLeaf Analytics and AJD Media to present the H2 2021 FreshLeaf Analytics Market Report.
This report will be the 7th major publication from FreshLeaf, who has been covering the Australian medical cannabis industry since 2017, and is the leading source of information, data and insight on the sector.